Scientific Programs

Sepsis is caused by a severe infection that enters the bloodstream and is associated with a high mortality rate. This high mortality rate has remained unchanged over the last three decades even though there has been active research in the area. The primary complication of sepsis that contributes to its high mortality is the severe

Following removal of the primary tumor and adjuvant chemotherapy, the development of lung metastasis is the most common cause of mortality in dogs with osteosarcoma. A distinctive feature of lung metastases of osteosarcoma in human patients is the surprising benefit that can result from surgical resection of the lung nodules. The use of surgery to

Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second drug, Encequidar, which improves this issue of poor

We propose that the spontaneous, but strongly genetic-based model of canine Necrotizing meningoencephalitis (NME) presents a unique way to help demonstrate the feasibility of inflammatory neurological disease prevention therapy.

Neutropenia (low white blood cell count) is a common side effect of chemotherapy in patients with cancer, with sepsis being a potential consequence. The timely identification and treatment of sepsis is paramount to the success of therapy.

Hemangiosarcoma (HSA) is an aggressive cancer in dogs and carries a poor prognosis. There are limited therapeutic options for the treatment of HSA, with none currently providing a significant opportunity for long-term survival.

This study is looking to evaluate the pharmacology profile of CBD in dogs (i.e. how it’s processed in the body) as well as its effectiveness in treating pain in dogs with chronic osteoarthritis. This study will hopefully result in similar studies being conducted in the fields of Neurology and Oncology.

Based on its reported tolerability in dogs (alone and in combination with chemotherapy) this study will ask whether Rapamycin may improve treatment outcomes for dogs with hemangiosarcoma, and more precisely, to understand the hemangiosarcoma genotypes which may most benefit from its use.

We have previously reported on the tolerability and hints of clinical activity of Sorafenib in dogs with cancer. This background provides a rationale for the further study of Sorafenib in dogs with cancer. In this study we seek to define an optimal dosing schedule for Sorafenib and will assess its tolerability and activity in dogs with solid tumors.

Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. To date, no studies have been published investigating the intestinal microbiome in dogs or humans with osteosarcoma (OSA). The objective of this study is to determine whether or not canine patients diagnosed with OSA have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.

The goal of this study is to evaluate changes in procalcitonin levels over time in canine patients surgically treated for sepsis secondary to an abdominal cause (i.e. ruptured intestine). Additional blood sample collection will also be performed to investigate for possible novel markers for sepsis using next generation sequencing for the future development of diagnostic test.